Cell and Gene Therapy Manufacturing Forum News

Back by popular demand, the 2019 industry heatmap provides a high level overview of the latest developments in the European novel therapy manufacturing space across The United Kingdom, Belgium, Greece and Switzerland, among others. 

With the 2018 commercialisation of prominent Autologous therapies such as KITEs Yskarta and Novartis’ Kymriah in the global market, more and more companies are beginning to move towards commercially based products. Yet despite these unquestionable industry growths, challenging issues can hinder – and even halt – groundbreaking progress in its tracks. There are still no established routes to market and with continuous changes in regulatory requirements across different global markets achieving any form of standardisation is difficult.

Download this free resource to gain valuable insights on some of the biggest challenges:

• globalising production and commercialisation
• scalability
• cost efficiency
• regulatory pathways
• supply and logistics

Joining this year’s curated programme will take you through a series of sessions from translation and collaboration to ensuring GMP compliance and optimising scalability. This year’s forum is also your one-stop shop for:

• Building manufacturing capabilities that are compliant, efficient and commercial
• Engaging in our GMP compliance training day to ensure that your process development optimisation does not come at the cost of process compliance
• Hearing from 18+ industry experts to benchmark your manufacturing practices and taking home industry leading solutions
• Optimising your manufacturing processes from end-to-end with topics covering every stage of the manufacturing process
• Helping to plan for your transition towards manufacturing at scale to ensure that your next therapy is market ready
• Gaining a practical understanding of data integrity issues and how it relates to manufacturing
• Exploring how to best identify, reduce and prevent potential data integrity breaches

To find out more information on the sessions, download the full agenda of the conference here. To request a copy to be sent via email, please click here.

Optimise every facet of your manufacturing strategy by participating at the Cell and Gene Therapy Manufacturing Forum.

Benefits of attending: 

• Join a curated programme taking you from translation and collaboration to ensuring GMP compliance and optimising scalability - this year’s forum is your one-stop shop for building manufacturing capabilities that are compliant, efficient and commercial
• Engage in our GMP compliance training day to ensure that your process development optimisation does not come at the cost of process compliance
• Hear from 18+ industry experts to benchmark your manufacturing practices and take home industry leading solutions
• Optimise your manufacturing process from end-to-end with topics covering every stage of the manufacturing process
• Plan for your transition towards manufacturing at scale to ensure that your next therapy is market ready

Pharma IQ spoke to Dr Ryan Guest, Director of Cell Production from cell therapy manufacturer Cellular Therapeutics to explore the raft of emerging trends connected to cell and gene manufacturing.

In this interview Pharma IQ speak to James Sherley to find out what have been the major advancements in using stem cells for toxicology testing and the current challenges that need to be overcome in using stem cells for toxicology. In this interview you will also find out what are going to be the trends in using stem cells for toxicology over the coming 18 months.

Pharma IQ has created an easy-to-digest overview of biomanufacturing activity and spend around the world, whether they are already being implemented or have plans in the near future. You’ll be able to keep it as a handy reference, share it around your colleagues or even stick it on your wall!

When introducing a regenerative medicine cell based product to a commercial setting, there are a number of things to take into consideration to ensure a commercially viable and safe product for patient use. In this Q&A interview, William Fodor, Director of Translational Sciences, Cell Therapy Group, gives some great insights into the commercial manufacturing scale-up process of cell therapies.

Magda Papadaki, Head of Manufacturing Innovation, The Association of the British Pharmaceutical Industry (ABPI) shares her presentation from last year's Cell & Gene Therapy Manufacturing Forum: 'Identify the Opportunities and Challenges in Advanced Therapy Manufacturing Process (ATMP)'.

In this presentation:

• Determine what to consider when moving from research to commercial production
• Understand what different set backs will become apparent when looking at cost efficiency of manufacturing 
• Hear the recommended actions that need to be considered when in the positions of discovery and development of advanced therapies